Abstract
The recent publication of a systematic review and meta-analysis of published and unpublished data from controlled trials on the effects of reboxetine in the acute treatment of major depression (Eyding et al, 2010) has reignited the debate surrounding the publication of negative trials by pharmaceutical companies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have